CVS Opioid Settlement: CVS to Pay $315 Million to End DOJ's False Claims Act Dispensing Case

The CVS opioid settlement announced by the Justice Department on Tuesday, October 13, 2026 requires CVS Pharmacy Inc. and related companies to pay $315 million to resolve allegations that, between October 17, 2013 and December 2, 2025, the chain filled invalid prescriptions for opioids and other controlled substances and then billed Medicare and other federal health programs for many of them. It ends both a 2019 whistleblower suit brought by a former CVS employee and the government's December 2024 nationwide complaint in the District of Rhode Island, and CVS admits no liability.

The deal is the federal government's second nine-figure resolution with a national pharmacy chain over opioid dispensing in eighteen months, after Walgreens settled a parallel case in April 2025. For lawyers following the opioid litigation, it closes the main remaining federal enforcement exposure CVS faced on dispensing, leaves the relator's award still to be fixed, and adds a compliance regime under the Drug Enforcement Administration that plaintiffs in any surviving private or local-government cases will read closely.

How much is the CVS opioid settlement with the DOJ?

CVS will pay $315 million. The Justice Department, the U.S. Attorney's Office for the District of Rhode Island, and the DEA each announced the figure on October 13, 2026. The public announcements describe the payment as resolving two sets of claims at once: civil liability under the Controlled Substances Act (CSA) for filling prescriptions that were not issued for a legitimate medical purpose, and liability under the False Claims Act (FCA) for submitting claims to federal health programs for those same prescriptions.

The public releases reported so far do not break the $315 million into a CSA civil-penalty component and an FCA damages component, and they do not describe an installment schedule. That matters for two practical reasons. First, a relator's share under the FCA is calculated only on the FCA proceeds, not on CSA penalties. Second, the split governs how much of the payment the company can characterize as restitution rather than a penalty. When the settlement agreement itself is posted, the allocation will be the first number practitioners look for. In the Walgreens deal, by comparison, the government split a $300 million base payment evenly: $150 million in CSA penalties and $150 million in FCA damages.

Why did CVS agree to pay $315 million?

The government's theory, laid out in the complaint it filed on December 13, 2024 and publicized on December 18, 2024, was that CVS pharmacies dispensed controlled substances that pharmacists knew or should have known were invalid, and that corporate policy made it hard for them to do otherwise. According to the Justice Department, the chain:

• Filled prescriptions for dangerous and excessive quantities of opioids.
• Filled opioid prescriptions too early, before a prior supply should have run out.
• Dispensed so-called trinity prescriptions combining an opioid, a benzodiazepine, and a muscle relaxant.
• Filled prescriptions written by prescribers it knew or should have known were operating "pill mills."
• Ignored red flags surfaced by its own pharmacists and by internal data.

The structural allegation is the one with the longest tail. The complaint alleged that CVS set staffing levels too low for pharmacists to both hit corporate performance metrics and meet their legal duty to verify prescriptions, that incentive compensation rewarded speed, and that the company withheld information pharmacists needed, including by preventing pharmacists from warning one another about particular prescribers. In announcing the 2024 complaint, the Civil Division said CVS had "pressured its pharmacists to fill such prescriptions without taking the time needed to confirm their validity."

The FCA count follows from the CSA count. A prescription that is not issued for a legitimate medical purpose is not a valid prescription, and a claim to Medicare Part D or another federal program for an invalid prescription is, on the government's theory, a false claim. That linkage is how a dispensing case becomes a fraud case with treble damages and per-claim penalties attached, and it explains why the government pursued both statutes in one complaint.

What are trinity prescriptions?

A trinity prescription, sometimes called a "holy trinity," is a combination of an opioid, a benzodiazepine, and a muscle relaxant such as carisoprodol, dispensed together to the same patient. Each drug depresses the central nervous system, and the combination substantially raises the risk of overdose and respiratory failure. The DEA and state pharmacy boards have long treated the pattern as a red flag that a pharmacist must resolve before dispensing, which is why it features in every major federal pharmacy-dispensing complaint, including the earlier Walgreens case.

Did CVS admit wrongdoing in the opioid settlement?

No. CVS said it strongly disagrees with the allegations and that the settlement is not an admission of wrongdoing. The Justice Department's own release states that the claims resolved are allegations only and that there has been no determination of liability. In statements to reporters, the company said its pharmacists are trained in the safe and appropriate use of all medications and pointed to what it called best-in-class programs to prevent diversion. When the complaint was filed in 2024, CVS argued that pharmacists had been held to "vague, undefined, and ever-changing standards of practice."

The no-admission structure is standard for civil FCA resolutions and tracks the language CVS used in its 2022 national opioid settlement. Its practical significance is limited but real: the settlement cannot be offered as an admission of liability in other proceedings, so plaintiffs elsewhere gain the government's investigative narrative but not an evidentiary concession.

Who is the CVS opioid whistleblower, and how much will she receive?

The settlement resolves a qui tam action filed under the FCA's whistleblower provisions by Hillary Estright, a former CVS employee. The case is captioned United States ex rel. Estright v. CVS Health Corp., et al., No. 1:22-cv-00222 (D.R.I.), and the United States intervened. Multiple outlets report that her share of the recovery has not yet been determined.

The statute sets the range. When the government intervenes, 31 U.S.C. § 3730(d)(1) entitles a relator to between 15% and 25% of the proceeds of the action or settlement of the claim, depending on how substantially the relator contributed to the prosecution. Applied to the full $315 million, that band would run from about $47 million to about $79 million. Applied only to whatever portion is allocated to FCA damages, the figure could be much lower. The Walgreens relators, by comparison, shared 17.25% of that deal, which came to more than $25 million.

One date in the record is worth noting. The Justice Department dates Estright's filing to October 17, 2019, and the covered conduct period begins on October 17, 2013, exactly six years earlier. The FCA's general limitations period is six years from the violation under 31 U.S.C. § 3731(b)(1), and the government's intervening complaint can relate back to the relator's filing. The matching dates suggest the conduct window was drawn to the edge of that six-year Statute of Limitations.

Timeline of the CVS opioid case

Date	Event
Oct. 17, 2013	Start of the conduct period covered by the settlement
2014-2018	Helena Foulkes serves as president of CVS Pharmacy (not a party to the case)
Oct. 17, 2019	Hillary Estright files her qui tam complaint under the False Claims Act
Nov. 2, 2022	CVS announces an agreement in principle on a roughly $5 billion national opioid settlement with states, local governments, and tribes
Dec. 13, 2024	United States files its complaint against CVS in the U.S. District Court for the District of Rhode Island
Dec. 18, 2024	Justice Department publicly announces the nationwide lawsuit
Apr. 21, 2025	Walgreens' federal settlement announced (up to $350 million)
Dec. 2, 2025	End of the conduct period covered by the settlement
Oct. 13, 2026	Justice Department announces the $315 million CVS settlement
Pending	Court determination or agreement on the relator's share

What does CVS have to change under the DEA agreement?

Alongside the payment, CVS entered into a separate agreement with the DEA. Based on the agency and press accounts, it requires CVS to establish a hotline through which employees and members of the public can report suspected illegal dispensing of controlled substances, to proactively monitor dispensing behavior across its pharmacies, and to maintain processes for evaluating prescribers suspected of issuing unlawful opioid prescriptions. The duration and auditing mechanics of the agreement were not described in the public announcements.

Assistant Attorney General Brett A. Shumate, who heads the Civil Division, said the settlement "requires CVS to implement additional safeguards to ensure that prescriptions for opioids and other controlled substances are dispensed only when medically appropriate," and singled out proactive monitoring of opioid prescribing patterns as a protection for patients and federal health programs. Associate Attorney General Stanley E. Woodward Jr. called it "a significant milestone" in the department's effort against pharmacies that unlawfully fill controlled-substance prescriptions. First Assistant U.S. Attorney Charles Calenda of the District of Rhode Island emphasized that pharmacies must maintain compliance systems capable of identifying unlawful prescriptions. According to the DEA release, the Rhode Island office worked the case with the U.S. Attorney's Offices for the Eastern District of Virginia, the Eastern District of Texas, and the District of Hawaii.

Notably, the reported terms describe monitoring and reporting obligations rather than prescriptive changes to the staffing and metrics policies at the center of the complaint. Whether the full agreement addresses pharmacist workload directly will be clear only when it is published.

How does the CVS settlement compare with the Walgreens opioid settlement?

The two federal cases were built on the same template, and the outcomes are close in size. The differences are in structure.

Term	CVS (Oct. 2026)	Walgreens (Apr. 2025)
Headline amount	$315 million	Up to $350 million
Structure	Single reported figure; allocation not yet public	$300 million base plus $50 million if the company is sold, merged, or transferred before fiscal 2032
Allocation	Not disclosed in announcements	$150 million CSA penalties, $150 million FCA damages
Basis	Not described as ability-to-pay	Amount set based on ability to pay, per DOJ
Court	District of Rhode Island	Northern District of Illinois
Conduct period	Oct. 17, 2013 to Dec. 2, 2025	About Aug. 2012 to Mar. 1, 2023
Whistleblowers	One relator (Estright); share not yet set	Four former employees; 17.25% share, more than $25 million
Admission	None; CVS strongly disagrees	None; Walgreens disputed the legal theory
Compliance terms	DEA agreement: hotline, proactive dispensing monitoring, prescriber evaluation	DEA agreement on pharmacist verification of controlled-substance prescriptions

Two points stand out. First, the CVS conduct window runs almost three years later than Walgreens', to December 2, 2025, which means the government was alleging conduct continuing well after the 2022 national settlements were signed. Second, the Walgreens figure was explicitly calibrated to that company's ability to pay at a time of financial distress; the CVS announcement contains no such framing, which makes the CVS number the cleaner benchmark for what the government views as a negotiated value for a nationwide dispensing case.

Does the CVS DOJ settlement affect the 2022 $5 billion opioid settlement?

Not directly. The 2022 deal resolved opioid claims brought by states, political subdivisions, and tribes: CVS agreed to pay about $4.9 billion to states and local governments and about $130 million to tribes over ten years beginning in 2023, also without admitting liability. The new settlement resolves claims belonging to the United States itself, chiefly for federal health-program payments and CSA civil penalties, which the state and local releases did not and could not extinguish. CVS had also reached state-specific resolutions before the national deal, including a $484 million agreement with Florida.

The relationship between the two layers has already generated litigation elsewhere. In the Walgreens matter, a federal relator sought a share of the separate multistate payment, and a federal judge in Chicago declined in September 2026 to decide that claim and sent it to state courts. Any similar argument by a CVS relator would face the same jurisdictional and state-law obstacles.

Where the private opioid litigation against pharmacies stands

The federal settlement lands against a mixed record for pharmacy defendants in the Mass Tort litigation consolidated in the national opioid Multidistrict Litigation (MDL), MDL 2804, in the Northern District of Ohio. In the MDL's pharmacy bellwether, a 2021 jury found CVS, Walgreens, and Walmart liable to Lake and Trumbull counties, and the court later entered a roughly $650 million abatement judgment. In December 2024, however, the Supreme Court of Ohio, answering a question certified by the Sixth Circuit, held 5-2 that the Ohio Product Liability Act bars the counties' common-law public nuisance claims based on the sale of products, undercutting the legal foundation of that judgment.

That ruling is a reminder that the most durable exposure for pharmacies may sit with government enforcers, who sue on statutory theories such as the CSA and FCA rather than state public nuisance law. The CVS settlement resolves the federal government's version of that exposure, but it does not address state attorney general actions on other theories, hospital or third-party payor claims, or individual personal-injury suits, none of which were parties to the October 13 deal.

The Foulkes question

Much of the conduct period overlaps the 2014-2018 tenure of Helena Foulkes as president of CVS Pharmacy. Foulkes is now a Democratic candidate for governor of Rhode Island, and local coverage has focused on that overlap. She was not named in the government's lawsuit, and her campaign has said she reduced opioid dispensing by nearly 40% by cutting off more than 600 pill-mill prescribers. The political dispute does not affect the settlement's legal terms, but it guarantees continued scrutiny of the record in Rhode Island.

What it means for practitioners

For opioid plaintiffs' counsel. The government's complaint and the DEA agreement give a detailed public account of alleged staffing and metrics pressure across a 12-year window. Counsel pursuing remaining claims against pharmacies can use that account to frame discovery requests and identify witnesses, although the settlement itself is not an admission and cannot be offered as one.

For whistleblower counsel. The relator-share determination is now the live issue in the Estright case. The FCA's 15% to 25% band, the CSA/FCA allocation, and the relator's contribution to a case the government spent years developing will drive the number. The six-year alignment between the filing date and the start of the conduct period also illustrates how early filing preserves the recovery window.

For pharmacy and health-care defendants. Two national chains have now paid roughly comparable amounts on the same theory that corporate staffing and incentive policies can make dispensing violations knowing. Compliance programs that measure pharmacist throughput without a documented mechanism for resolving red flags carry FCA risk, not just regulatory risk.

For personal-injury and mass tort firms. The settlement pays the federal government, not individuals. People harmed by opioids dispensed at CVS do not receive compensation from this deal, and nothing in it creates a claims process or a Global Settlement for personal-injury claimants.

FAQ

How much did CVS agree to pay to settle the DOJ opioid case?

CVS agreed to pay $315 million, announced October 13, 2026, to resolve Controlled Substances Act and False Claims Act allegations covering October 17, 2013 through December 2, 2025.

Did CVS admit wrongdoing?

No. CVS said it strongly disagrees with the allegations, and the Justice Department said the claims are allegations only with no determination of liability.

Who brought the original CVS opioid lawsuit?

Former CVS employee Hillary Estright filed a qui tam suit in 2019, United States ex rel. Estright v. CVS Health Corp., No. 1:22-cv-00222 (D.R.I.); the United States filed its own complaint on December 13, 2024.

How much will the CVS whistleblower get?

The relator's share has not been set. Because the government intervened, the False Claims Act provides for 15% to 25% of the proceeds of the FCA claims.

Can individuals get money from the CVS $315 million settlement?

No. The payment goes to the United States to resolve federal claims; it is not a class or personal-injury settlement and has no claims process for individuals.

Is this the same as the $5 billion CVS opioid settlement?

No. The 2022 settlement of about $5 billion resolved claims by states, local governments, and tribes; the October 2026 settlement resolves claims belonging to the federal government.